While 2024 marked another “challenging” year for biotech stocks, some names could be slated for upside in the months ahead, according to JPMorgan.
Communicating your story to the Street
While 2024 marked another “challenging” year for biotech stocks, some names could be slated for upside in the months ahead, according to JPMorgan.